NUREXONE BIOLOGIC INC (NRX.CA) Stock Price, Forecast & Analysis
Canada • TSX Venture Exchange • TSX-V:NRX • CA67059R1091
NRX.CA Key Statistics, Chart & Performance
The current stock price of NRX.CA is 0.69 CAD. In the past month the price increased by 7.81%. In the past year, price increased by 13.11%.
NRX.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NRX.CA. When comparing the yearly performance of all stocks, NRX.CA turns out to be only a medium performer in the overall market: it outperformed 44% of all stocks.
NRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA. While NRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
NRX.CA Financial Highlights
Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -246.98% | ||
| ROE | -448.52% | ||
| Debt/Equity | 0.05 |
NRX.CA Forecast & Estimates
9 analysts have analysed NRX.CA and the average price target is 3.57 CAD. This implies a price increase of 417.39% is expected in the next year compared to the current price of 0.69.
NRX.CA Ownership
NRX.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 620.969M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 381.691M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 144.358M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 72.567M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.51 | 46.125M | ||
| RVX | RESVERLOGIX CORP | N/A | 31.607M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.45 | 30.578M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.907M | ||
| MPH | MEDICURE INC | N/A | 12.11M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 11.092M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About NRX.CA
Company Profile
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.
Company Info
NUREXONE BIOLOGIC INC
Minus 1 Entry, Ground Floor Of Bldg B, Gutwirth Industrial Park, Technion City, Haifa
Haifa ALBERTA IL
Employees: 12
Phone: 972524803034
NUREXONE BIOLOGIC INC / NRX.CA FAQ
What does NRX do?
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The firm focuses on research and development of pharmaceutical technologies.
What is the stock price of NUREXONE BIOLOGIC INC today?
The current stock price of NRX.CA is 0.69 CAD. The price decreased by -1.43% in the last trading session.
Does NRX stock pay dividends?
NRX.CA does not pay a dividend.
What is the ChartMill rating of NUREXONE BIOLOGIC INC stock?
NRX.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is NUREXONE BIOLOGIC INC (NRX.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NRX.CA.
Can you provide the market cap for NUREXONE BIOLOGIC INC?
NUREXONE BIOLOGIC INC (NRX.CA) has a market capitalization of 57.37M CAD. This makes NRX.CA a Micro Cap stock.